Keith Newton and the art of coming back

Keith Newton arrived at the New York Stock Exchange with a company whose history he knew from before it had its present name. On July 25, 2024, Concentra began trading under the symbol CON. Newton, its chief executive, was there for the opening bell. The photographs show a familiar exchange-day arrangement: colleagues gathered tightly, a corporate name overhead, a bell polished to a degree rarely achieved by ordinary office equipment.

The less photogenic part had taken decades. Newton joined OccuSystems in 1995, two years before the merger that formed Concentra. He rose through operations, left in 2011, and came back in 2015 to run the company. By the time the cameras assembled in New York, he was leading a business he had helped manage through several different chapters of ownership.

Now another date approaches. On November 1, 2026, Newton is scheduled to move from chief executive to executive chairman. Matt DiCanio, Concentra’s president and chief financial officer, will succeed him as CEO. It is a handoff between colleagues whose working relationship reaches back to Newton’s return. The interesting question is what a leader leaves in place when he changes seats.

The accountant before the opening bell

Newton earned his BBA in accounting at Texas A&M University in 1985. His early career included work as a CPA with KPMG Peat Marwick and accounting and finance roles at The Associates First Capital Corporation. The beginnings are refreshingly free of garage mythology. Before the operating titles came the accounts.

There was another strand to his university years. Newton’s public LinkedIn profile lists varsity football letterman among his activities at Texas A&M, where he studied from 1981 to 1985. It is a small detail beside the corporate appointments, but a useful reminder that an executive biography can flatten a person into a succession of desks.

From 1991 to 1995, he worked at Medical Care International and its successor, Columbia HCA’s Ambulatory Surgery Division. Then came OccuSystems. His route into Concentra therefore ran through finance and the management of an existing organization. He arrived before the brand, rather than inventing it afterward in a convenient founding legend.

That distinction matters to the shape of his career. Newton’s story is about operating a company as it changes: learning its workings, taking responsibility for more of them, and returning to familiar ground with a different job. The dates supply the evidence. Whatever the attractions of the overnight success story, this one requires a longer calendar.

Leaving, then coming back

From 1999 to 2007, Newton led one of Concentra’s divisions. In 2007, he became president and chief operating officer, a position he held until 2011. These were substantial stretches of responsibility before his eventual appointment as chief executive. His second tenure would rest on knowledge acquired in the first.

In 2011, he left for DentalOne Partners, where he held senior leadership responsibilities until 2015. That four-year interval gives his biography an unusual rhythm. A long relationship with one company can look inevitable when compressed into a paragraph. Here, the relationship included an actual departure, another organization, and a return.

He rejoined Concentra as president and CEO in June 2015. He subsequently served as chairman from 2018 to 2022, during the company’s joint-venture ownership by Select Medical, Welsh Carson, and other investors. He remained president until 2023 and continued as chief executive. The titles changed as the ownership arrangements changed around him.

There is a practical difference between knowing an organization’s history and having worked through it. Newton had been present before the 1997 merger and had run operations years before the 2024 listing. His career gives the public-company chapter a substantial preface. Concentra was new to that stock ticker; its CEO was thoroughly acquainted with the business.

The relationship that took ten years

In January 2025, Concentra announced an agreement to acquire Nova Medical Centers in a transaction valued at $265 million, subject to adjustment. Nova operated 67 locations across five states. An announcement can fit those numbers into a few lines. Newton’s account of the relationship behind it required a much longer unit of time.

Speaking with interviewer Joe Paduda the following month, he described a relationship developed over ten years. He also pointed to the complementary geography. Concentra had concentrated on large metropolitan areas; Nova had experience in smaller cities in south Texas. The attraction included places the buyer knew less well.

“In every transaction we do we always learn something”

Keith Newton, February 2025

That observation gives the deal a more interesting texture than the usual arithmetic of adding locations. Newton described evaluating Nova’s technology and operating model before integration. His account allowed for the acquired organization to contribute knowledge. The buyer would bring its name and systems; the acquired business had experience worth examining.

Corporate language often makes acquisition sound like an act of tidying: absorb the assets, change the signs, proceed. Newton’s explanation was more curious than that. The smaller-city experience was part of the appeal. For an executive with decades inside his own organization, acknowledging something to learn from another one is a useful working habit.

Two dates for independence

The 2024 listing has its own precise sequence. Concentra priced 22.5 million shares at $23.50 each. Trading began on July 25; the offering closed on July 26. Gross proceeds from that initial offering were $528.8 million. These are company financing figures, a measure of the transaction rather than Newton’s personal fortune.

The opening bell supplied the ceremony, but Select Medical still held a controlling interest afterward. Full separation came on November 25, 2024, when Select distributed its remaining Concentra shares to its stockholders. The summer listing and the autumn spin-off were separate events. A memorable photograph tends to compress them into one.

Newton was still dealing with the practical consequences in early 2025. He described the remaining separation of shared functions, including payroll and benefits administration, technology support, finance reporting, and legal support. Ownership could be separated on an appointed date. The systems that kept the company functioning required their own work.

This is where his career becomes particularly legible. The accountant, the divisional president, and the operating chief all belong in the same story as the CEO at the bell. Independence creates administrative demands alongside strategic possibilities. Someone has to make the payroll arrangements work after the celebratory photographs have been filed away.

What “Newt” says about the team

On Concentra’s careers page, Newton signs his message as Keith “Newt” Newton. The nickname is a welcome interruption in the formal furniture of executive titles. In that message he describes a culture built around “support, trust, honesty, and service.” He also writes about colleagues being able to advance as far as their ambition takes them.

Those are his stated priorities, and a useful way to read his public account of leadership. He repeatedly assigns credit to colleagues. When discussing the November 2026 transition, he singled out DiCanio’s role in shaping the strategy and driving performance. The announced succession had been developed over multiple years and approved unanimously by the board.

The relationship with DiCanio has a history of its own. DiCanio joined Concentra in 2015 in strategy and corporate development, became an executive vice president in 2021, president in 2023, and CFO in 2024. His planned elevation to CEO follows a progression across responsibilities, alongside Newton’s second tenure at the company.

The succession announcement arrived alongside Concentra’s second-quarter 2026 results: revenue of $606 million, compared with $550.8 million a year earlier, an increase of 10 percent. Newton would be changing roles after a quarter of reported growth. Those figures provide context for the timing, while the multiyear planning behind the appointments places the handoff within a longer process of preparing the next leadership team.

The outgoing chief executive’s institutional memory will remain available. Robert Ortenzio is scheduled to step down as chairman while continuing as a director, and Newton will become executive chairman. The arrangement changes who holds day-to-day executive authority while keeping experienced colleagues involved in the boardroom. Continuity has been designed into the appointments.

In an August 2026 earnings call, Newton described decision-making as a collaborative process involving experienced managers beyond himself and DiCanio. It is his description of how the organization works, rather than a claim that longevity alone produces good decisions. The revealing detail is the breadth of participation he emphasized: colleagues contributing to strategy and then taking responsibility for carrying it out.

A different chair, the same company

As of October 22, 2026, Newton remains CEO. The November appointment is still ahead. His stated responsibilities as executive chairman will include supporting strategic initiatives and leadership development. That gives the next chapter a defined purpose beyond the ceremonial reward sometimes implied by a change of title.

The final weeks before that handoff offer a useful vantage point on his working life. There is the 1985 accounting degree, the 1995 arrival, the departure and return, the listing, and the task of separating a business from its former parent. Each stage adds another kind of responsibility to the same long association.

At the exchange, the bell marked a precise moment. The career behind it has been less tidy, and more interesting: a return, a ten-year relationship behind a deal, a company becoming independent in stages. Newton’s next task is to help another leader carry that accumulated experience forward. The office title will change. The history comes with him.